Attenuation of the pressor response to exogenous angiotensin by angiotensin receptor blockers and benazepril hydrochloride in clinically normal cats

Am J Vet Res. 2015 Sep;76(9):807-13. doi: 10.2460/ajvr.76.9.807.

Abstract

Objective: To compare the attenuation of the angiotensin I-induced blood pressure response by once-daily oral administration of various doses of angiotensin receptor blockers (irbesartan, telmisartan, and losartan), benazepril hydrochloride, or lactose monohydrate (placebo) for 8 days in clinically normal cats.

Animals: 6 healthy cats (approx 17 months old) with surgically implanted arterial telemetric blood pressure-measuring catheters.

Procedures: Cats were administered orally the placebo or each of the drug treatments (benazepril [2.5 mg/cat], irbesartan [6 and 10 mg/kg], telmisartan [0.5, 1, and 3 mg/kg], and losartan [2.5 mg/kg]) once daily for 8 days in a crossover study. Approximately 90 minutes after capsule administration on day 8, each cat was anesthetized and arterial blood pressure measurements were recorded before and after IV administration of each of 4 boluses of angiotensin I (20, 100, 500, and 1,000 ng/kg). This protocol was repeated 24 hours after benazepril treatment and telmisartan (3 mg/kg) treatment. Differences in the angiotensin I-induced change in systolic arterial blood pressure (ΔSBP) among treatments were determined.

Results: At 90 minutes after capsule administration, only losartan did not significantly reduce ΔSBP in response to the 3 higher angiotensin doses, compared with placebo. Among drug treatments, telmisartan (3 mg/kg dosage) attenuated ΔSBP to a significantly greater degree than benazepril and all other treatments. At 24 hours, telmisartan was more effective than benazepril (mean ± SEM ΔSBP, 15.7 ± 1.9 mm Hg vs 55.9 ± 12.42 mm Hg, respectively).

Conclusions and clinical relevance: Results indicated that telmisartan administration may have advantages over benazepril administration for cats with renal or cardiovascular disease.

Publication types

  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / administration & dosage
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Animals
  • Benzazepines / administration & dosage
  • Benzazepines / pharmacology*
  • Benzimidazoles / pharmacology*
  • Benzoates / pharmacology*
  • Biphenyl Compounds / pharmacology*
  • Blood Pressure / drug effects*
  • Cats / physiology*
  • Cross-Over Studies
  • Irbesartan
  • Losartan / administration & dosage
  • Losartan / pharmacology*
  • Telmisartan
  • Tetrazoles / pharmacology*

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Benzazepines
  • Benzimidazoles
  • Benzoates
  • Biphenyl Compounds
  • Tetrazoles
  • Irbesartan
  • Losartan
  • Telmisartan
  • benazepril